Investors pulled a record $372 million from the biggest biotechnology exchange traded fund in its worst day of redemptions ever.
John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.
Sanofi-Aventis SA made a takeover approach to Genzyme Corp. , the largest maker of medicines for genetic diseases, about two weeks ago, said two people with knowledge of the matter.
Harris Corp. a maker of communications-related electronic equipment, sued Netgear Inc. for allegedly infringing network-security patents.
Dendreon Corp. rose the most in a year on optimism that more patients will begin taking the biotechnology company’s prostate cancer drug Provenge.
Amgen Inc., the world’s largest biotechnology company, agreed to buy Micromet Inc. in a $1.16 billion deal to gain an experimental leukemia drug.
Vertex Pharmaceuticals Inc. rose in New York trading after its hepatitis C drug made treatment quicker and more effective in a study that may lead to $1.8 billion in annual U.S. sales.
Merck & Co. won a U.S. panel’s backing to sell an experimental hepatitis C drug that cured more patients in clinical trials than current therapies.
Vertex Pharmaceuticals Inc. rose 12 percent in intraday trading after U.S. regulators said the company’s experimental hepatitis C drug cures more patients than current therapies.
Dendreon Corp. rose after winning the backing of European Union regulators for the prostate cancer treatment Provenge, the company’s only marketed product.
"We consider the sector's run-up, which has been remarkable, to be getting into its very final innings."
- Geoffrey Porges on Apr 07, 2014